FAM98A associates with DDX1-C14orf166-FAM98B in a novel complex involved in colorectal cancer progression

International Journal of Biochemistry and Cell Biology

Volumn 84, Issue , 2017, Pages 1-13

  Akter, Khondker Ayesha ^a   Mansour, Mohammed A ^b   Hyodo, Toshinori ^c   Senga, Takeshi ^c  

^a NORTH SOUTH UNIVERSITY   (Bangladesh)

^b Tanta University   (Egypt)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; FAM98A; FAM98B; PRMT1

Indexed keywords

ARGININE; PROTEIN; PROTEIN C14ORF166; PROTEIN DDX1; PROTEIN FAM98A; PROTEIN FAM98B; PROTEIN PRMT1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; C14ORF166 PROTEIN, HUMAN; CARRIER PROTEIN; DDX1 PROTEIN, HUMAN; DEAD BOX PROTEIN; FAM98A PROTEIN, HUMAN; FAM98B PROTEIN, HUMAN; MESSENGER RNA; MULTIPROTEIN COMPLEX; PRMT1 PROTEIN, HUMAN; PROTEIN ARGININE METHYLTRANSFERASE; REPRESSOR PROTEIN; RNA; TRANSACTIVATOR PROTEIN;

ADULT; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER GROWTH; CANCER TISSUE; CELL PROLIFERATION; COLONY FORMATION; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC DATABASE; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; MALE; METHYLATION; MOLECULAR PATHOLOGY; PROTEIN DEPLETION; PROTEIN PROTEIN INTERACTION; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DISEASE COURSE; GENE SILENCING; GENETICS; HCT 116 CELL LINE; HT-29 CELL LINE; METABOLISM; TUMOR STEM CELL ASSAY;

CARRIER PROTEINS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DEAD-BOX RNA HELICASES; DISEASE PROGRESSION; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HT29 CELLS; HUMANS; MULTIPROTEIN COMPLEXES; PROTEIN-ARGININE N-METHYLTRANSFERASES; PROTEINS; REPRESSOR PROTEINS; RNA, MESSENGER; RNA, NEOPLASM; TRANS-ACTIVATORS; TUMOR STEM CELL ASSAY;

EID: 85008975719     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2016.12.013     Document Type: Article

References (39)

1. Akter, K.A., Mansour, M.A., Hyodo, T., Ito, S., Hamaguchi, M., Senga, T., FAM98A is a novel substrate of PRMT1 required for tumor cell migration, invasion and colony formation. Tumour Biol. 37:4 (2016), 4531–4539, 10.1007/s13277-015-4310-5.
2. Ayesha, A.K., Hyodo, T., Asano, E., Sato, N., Mansour, M.A., Ito, S., et al. UBE2S is associated with malignant characteristics of breast cancer cells. Tumour Biol. 37:1 (2016), 763–772, 10.1007/s13277-015-3863-7.
3. Baldwin, R.M., Morettin, A., Côté, J., Role of PRMTs in cancer: could minor isoforms be leaving a mark?. World J. Biol. Chem. 5:2 (2014), 115–129.
4. Bedford, M.T., Clarke, S.G., Protein arginine methylation in mammals: who, what, and why. Mol. Cell 33:1 (2009), 1–13.
5. Bedford, M.T., Richard, S., Arginine methylation an emerging regulator of protein function. Mol. Cell 18:3 (2005), 263–272.
6. Cheang, T., Zhou, H., Chen, W., Zhang, B., Liu, L., Yang, J., et al. C14orf166 overexpression correlates with tumor progression and poor prognosis of breast cancer. J. Transl. Med., 2016, 14–54, 10.1186/s12967-016-0805-0.
7. Chen, M., Ye, Y., Zou, B., Guo, S., Zhou, F., Lu, K., et al. C14orf166 is a high-risk biomarker for bladder cancer and promotes bladder cancer cell proliferation. J. Transl. Med., 2016, 14–55, 10.1186/s12967-016-0801-4.
8. Cheng, X., Collins, R.E., Zhang, X., Structural and sequence motifs of protein (histone) methylation enzymes. Annu. Rev. Biophys. Biomol. Struct. 34 (2005), 267–294.
9. Cheung, N., Chan, L.C., Thompson, A., Cleary, M.L., So, C.W., Protein arginine-methyltransferase-dependent oncogenesis. Nat. Cell Biol. 9:10 (2007), 1208–1215.
10. Cui, Y., Wu, J., Zong, M., Song, G., Jia, Q., Jiang, J., Han, J., Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int. J. Cancer 124:7 (2009), 1614–1621, 10.1002/ijc.24163.
11. Debler, E.W., Jain, K., Warmack, R.A., Feng, Y., Clarke, S.G., Blobel, G., et al. A glutamate/aspartate switch controls product specificity in a protein arginine methyltransferase. Proc. Natl. Acad. Sci. U. S. A. 113:8 (2016), 2068–2073.
12. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136:5 (2015), E359–386.
13. Gao, Y., Zhao, Y., Zhang, J., Lu, Y., Liu, X., Geng, P., et al. The dual function of PRMT1 in modulating epithelial-mesenchymal transition and cellular senescence in breast cancer cells through regulation of ZEB1. Sci. Rep., 6, 2016, 19874.
14. Gary, J.D., Clarke, S., RNA and protein interactions modulated by protein arginine methylation. Prog. Nucleic Acid Res. Mol. Biol. 61 (1998), 65–131.
15. Goulet, I., Gauvin, G., Boisvenue, S., Côté, J., Alternative splicing yields protein arginine methyltransferase 1 isoforms with distinct activity, substrate specificity, and subcellular localization. J. Biol. Chem. 282:45 (2007), 33009–33021.
16. Han, C., Liu, Y., Wan, G., Choi, H.J., Zhao, L., Ivan, C., et al. The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression. Cell Rep. 8:5 (2014), 1447–1460, 10.1016/j.celrep.2014.07.058.
17. Le romancer, M., Treilleux, I., Bouchekioua-bouzaghou, K., Sentis, S., Corbo, L., Methylation, a key step for nongenomic estrogen signaling in breast tumors. Steroids 75:8- 9 (2010), 560–564.
18. Li, L., Zhang, Z., Ma, T., Huo, R., PRMT1 regulates tumor growth and metastasis of human melanoma via targeting ALCAM. Mol. Med. Rep. 14:1 (2016), 521–528.
19. Mansour, M.A., Hyodo, T., Ito, S., Kurita, K., Kokuryo, T., Uehara, K., et al. SATB2 suppresses the progression of colorectal cancer cells via inactivation of MEK5/ERK5 signaling. FEBS J. 282:8 (2015), 1394–1405.
20. Mansour, M.A., Asano, E., Hyodo, T., Akter, K.A., Takahashi, M., Hamaguchi, M., Senga, T., Special AT-rich sequence-binding protein 2 suppresses invadopodia formation in HCT116 cells via palladin inhibition. Exp. Cell. Res. 332:1 (2015), 78–88.
21. Mansour, M.A., Hyodo, T., Akter, K.A., Kokuryo, T., Uehara, K., Nagino, M., Senga, T., SATB1 and SATB2 play opposing roles in c-Myc expression and progression of colorectal cancer. Oncotarget 7:4 (2016), 4993–5006.
22. Mathioudaki, K., Papadokostopoulou, A., Scorilas, A., Xynopoulos, D., Agnanti, N., Talieri, M., The PRMT1 gene expression pattern in colon cancer. Br. J. Cancer 99:12 (2008), 2094–2099.
23. Mathioudaki, K., Scorilas, A., Ardavanis, A., Lymberi, P., Tsiambas, E., Devetzi, M., Clinical evaluation of PRMT1 gene expression in breast cancer. Tumour Biol. 32:3 (2011), 575–582.
24. Pérez-gonzález, A., Pazo, A., Navajas, R., Ciordia, S., Rodriguez-frandsen, A., Nieto, A., hCLE/C14orf166 associates with DDX1-HSPC117-FAM98B in a novel transcription- dependent shuttling RNA-transporting complex. PLoS One, 9(3), 2014, e90957.
25. Popow, J., Englert, M., Weitzer, S., Schleiffer, A., Mierzwa, B., Mechtler, K., et al. HSPC117 is the essential subunit of a human tRNA splicing ligase complex. Science 331:6018 (2011), 760–764.
26. Rajpurohit, R., Paik, W.K., Kim, S., Effect of enzymic methylation of heterogeneous ribonucleoprotein particle A1 on its nucleic-acid binding and controlled proteolysis. Biochem. J. 304:Pt. 3 (1994), 903–909.
27. Seligson, D.B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M., et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435:7046 (2005), 1262–1266.
28. Siegel, R., Desantis, C., Jemal, A., Colorectal cancer statistics. CA Cancer J. Clin. 64:2 (2014), 104–117.
29. Smith, J.J., Rücknagel, K.P., Schierhorn, A., Tang, J., Nemeth, A., Linder, M., et al. Unusual sites of arginine methylation in Poly(A)-binding protein II and in vitro methylation by protein arginine methyltransferases PRMT1 and PRMT3. J. Biol. Chem. 274:19 (1999), 13229–13234.
30. Stallcup, M.R., Role of protein methylation in chromatin remodeling and transcriptional regulation. Oncogene 20:24 (2001), 3014–3020.
31. The Cancer Genome Atlas. Colorectal Adenocarcinoma (TCGA, Provisional). http://www.cbioportal.org/study?id=coadread_tcga #summary.
32. Wada, K., Inoue, K., Hagiwara, M., Identification of methylated proteins by protein arginine N- methyltransferase 1, PRMT1, with a new expression cloning strategy. Biochim. Biophys. Acta 1591:1–3 (2002), 1–10.
33. Yang, Y., Bedford, M.T., Protein arginine methyltransferases and cancer. Nat. Rev. Cancer 13:1 (2013), 37–50.
34. Yang, L., Li, F., Lei, F., Wang, Y., Wu, S., Song, L., Chen, Y., Overexpression of chromosome 14 open reading frame 166 correlates with disease progression and poorer prognosis in human NPC. Tumour Biol. 36:10 (2015), 7977–7986, 10.1007/s13277 -015-3518-8.
35. Yoshimatsu, M., Toyokawa, G., Hayami, S., Unoki, M., Tsunoda, T., Field, H.I., Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int. J. Cancer. 128:3 (2011), 562–573.
36. Zauber, A.G., The impact of screening on colorectal cancer mortality and incidence: has it really made a difference?. Dig. Dis. Sci. 60:3 (2015), 681–691.
37. Zhang, X., Cheng, X., Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides. Structure 11:5 (2003), 509–520.
38. Zhang, W., Ou, J., Lei, F., Hou, T., Wu, S., Niu, C., et al. C14ORF166 overexpression is associated with pelvic lymph node metastasis and poor prognosis in uterine cervical cancer. Tumour Biol. 37:1 (2016), 369–379, 10.1007/s13277-015-3806-3.
39. Zou, L., Zhang, H., Du, C., Liu, X., Zhu, S., Zhang, W., et al. Correlation of SRSF1 and PRMT1 expression with clinical status of pediatric acute lymphoblastic leukemia. J. Hematol. Oncol., 5, 2012, 42.